Comparison · NCT05295459-c0d0d3dd
LYR-210 vs Sham Procedure Control: Rescue Treatment Requirement Through Week 24
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LYR-210 vs Sham Procedure Control: Rescue Treatment Requirement Through Week 24. Trial comparisons, record NCT05295459-c0d0d3dd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05295459-c0d0d3dd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.108 | 0.0629 | 0.18 | wilson | |
| Risk in group 2 | 0.115 | 0.0567 | 0.218 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00665 | -0.12 | 0.0854 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.942 | 0.391 | 2.27 | log | |
| Odds ratio, group 1 over group 2 | 0.935 | 0.348 | 2.51 | log | |
| Number needed to treat, for one fewer participant with the outcome on LYR-210 than on Sham Procedure Control | 150 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: sham.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LYR-210 | Single administration of LYR-210 drug matrix (7500 μg)~LYR-210: LYR-210 drug matrix (mometasone furoate)~Background therapy: Daily Saline Irrigation | 12 | 111 | OG000 |
| Group 2 | Sham Procedure Control | Single mock administration procedure~Sham procedure control: Sham procedure control~Background therapy: Daily Saline Irrigation | 7 | 61 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Rescue Treatment Requirement Through Week 24
- Description
- Number and percent of participants requiring rescue treatment (systemic corticosteroid for any reason or participants that were recommended/underwent sinonasal surgery) through Week 24.
- Time frame
- Week 24
- Population
- ITT Analysis Set
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
- NCT number
- NCT05295459
- Phases
- PHASE3
- Conditions
- Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
- Interventions
- LYR-210, Sham procedure control, Background therapy
- Lead sponsor
- Lyra Therapeutics
- Results first posted
- 2026-02-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05295459?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05295459-c0d0d3dd